Neurogene, Inc., a NYC-based company founded with a mission to bring life-changing medicines to patients and families affected by rare neurological diseases, raised $68.5m in Series A financing.
Investors included Samsara BioCapital, EcorR1 Capital, Cormorant Asset Management, Redmile Group and an undisclosed leading healthcare investment fund.
The company intends to use the funds to advance multiple gene therapy programs into IND-enabling studies and clinical trials for patients with rare neurological diseases, invest in novel technologies for indications not addressed by traditional gene therapy approaches and establish a viral vector manufacturing facility.
Led by Rachel McMinn, Ph.D., Founder and Chief Executive Officer, Neurogene partners with academic researchers, patient advocacy organizations and caregivers to bring therapies to patients that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Its lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene.
The company is also investing in novel technologies to develop treatments for diseases not well served by gene therapy.
FinSMEs
12/02/2019
Contacts
Sara Green, Ten Bridge Communications
[email protected]
617-233-1714